Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 in Early Myelofibrosis
NCT02370329Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2015
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in myelofibrosis (MF), sponsored by Mayo Clinic. Started Aug 2015; status: terminated.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02370329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370329.